Summary
UnitedHealthcare Community Plan of Kentucky revised Xolair (omalizumab) coverage criteria effective October 1, 2026. Key changes include: (1) Added requirement for chronic urticaria patients to trial updosed 2nd generation H1-antihistamines (up to 4-fold) for 2 weeks before Xolair approval; (2) Expanded contraindicated combination therapy list across all indications to include Exdensur (depemokimab) and Nucala (mepolizumab). Billing teams must update prior authorization workflows to enforce new H1-antihistamine trial requirements and screen for drug interactions before claim submission.
Get alerts when payers change rules like this one
We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.
Get UnitedHealthcare alertsPolicy Monitoring is free. No card required.
What to do
by Sep 15, 2026 · 5 steps
01Billing and Prior Authorization teams must update UnitedHealthcare authorization system to require documentation of at least 2-week trial of standard-dosed 2nd generation H1-antihistamine (e.g., fexofenadine, loratadine, cetirizine) followed by 2-week trial of updosed (up to 4-fold) H1-antihistamine before approving Xolair for chronic urticaria indication.
02Update prior auth checklist/forms to include mandatory field requiring providers to confirm patient is NOT currently receiving: Exdensur (depemokimab) or Nucala (mepolizumab) for all four indications (asthma, chronic urticaria, nasal polyps, IgE-mediated food allergy).
03Train Prior Authorization staff on new contraindication screening requirements.
04Update denial templates to specifically reference missing H1-antihistamine trial documentation or active anti-IL-5 therapy conflict.
05Claims submitted without evidence of required H1-antihistamine trial or with concurrent anti-IL-5 therapy will be denied.
Original notice
Xolair ® (Omalizumab)
uhcprovider.com · Always check the source before changing claims.
Related changes
See all UnitedHealthcare changes →Xolair ® (Omalizumab)MediumEffective Oct 1, 2026 · Medical Benefit Drug PolicyXolair ® (Omalizumab)MediumEffective Oct 1, 2026 · Medical Benefit Drug PolicyXolair ® (Omalizumab)MediumEffective Oct 1, 2026 · Medical Benefit Drug PolicyXolair ® (Omalizumab)MediumEffective Oct 1, 2026 · Medical Benefit Drug PolicyBrowse every UnitedHealthcare change in the policy list